Aramis: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).

K Fizazi; ND Shore; T Tammela; A Ulys; E Vjaters; S Polyakov; M Jievaltas; M Luz; BY Alekseev; I Kuss; C Kappeler; A Snapir; T Sarapohja; MR Smith

doi:10.1200/JCO.2019.37.7_suppl.140

Aramis: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).

K Fizazi
, ND Shore
, T Tammela
, A Ulys
, E Vjaters
, S Polyakov
, M Jievaltas
, M Luz
, BY Alekseev
, I Kuss
, C Kappeler
, A Snapir
, T Sarapohja
, MR Smith

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	140
Number of pages	2
Journal	Journal of Clinical Oncology
Volume	37
Issue number	7 Suppl.
DOIs	https://doi.org/10.1200/JCO.2019.37.7_suppl.140
Publication status	Published - 1 Mar 2019
Externally published	Yes
Event	2019 Genitourinary Cancers Symposium - San Francisco, United States Duration: 14 Feb 2019 → 16 Feb 2019 https://dailynews.ascopubs.org/meetings/archive/2019/gu

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

10.1200/JCO.2019.37.7_suppl.140

Cite this

Fizazi, K., Shore, ND., Tammela, T., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, BY., Kuss, I., Kappeler, C., Snapir, A., Sarapohja, T., & Smith, MR. (2019). Aramis: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology, 37(7 Suppl.), Article 140. https://doi.org/10.1200/JCO.2019.37.7_suppl.140

@article{622d6e13db96454482db073ebacc54cb,

title = "Aramis: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).",

author = "K Fizazi and ND Shore and T Tammela and A Ulys and E Vjaters and S Polyakov and M Jievaltas and M Luz and BY Alekseev and I Kuss and C Kappeler and A Snapir and T Sarapohja and MR Smith",

year = "2019",

month = mar,

day = "1",

doi = "10.1200/JCO.2019.37.7\_suppl.140",

language = "English",

volume = "37",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "7 Suppl.",

note = "2019 Genitourinary Cancers Symposium ; Conference date: 14-02-2019 Through 16-02-2019",

url = "https://dailynews.ascopubs.org/meetings/archive/2019/gu",

}

Fizazi, K, Shore, ND, Tammela, T, Ulys, A, Vjaters, E, Polyakov, S, Jievaltas, M, Luz, M, Alekseev, BY, Kuss, I, Kappeler, C, Snapir, A, Sarapohja, T & Smith, MR 2019, 'Aramis: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).', Journal of Clinical Oncology, vol. 37, no. 7 Suppl., 140. https://doi.org/10.1200/JCO.2019.37.7_suppl.140

TY - JOUR

T1 - Aramis

T2 - 2019 Genitourinary Cancers Symposium

AU - Fizazi, K

AU - Shore, ND

AU - Tammela, T

AU - Ulys, A

AU - Vjaters, E

AU - Polyakov, S

AU - Jievaltas, M

AU - Luz, M

AU - Alekseev, BY

AU - Kuss, I

AU - Kappeler, C

AU - Snapir, A

AU - Sarapohja, T

AU - Smith, MR

PY - 2019/3/1

Y1 - 2019/3/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=rsu_pure_&SrcAuth=WosAPI&KeyUT=WOS:000489108800183&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1200/JCO.2019.37.7_suppl.140

DO - 10.1200/JCO.2019.37.7_suppl.140

M3 - Meeting Abstract

SN - 0732-183X

VL - 37

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 7 Suppl.

M1 - 140

Y2 - 14 February 2019 through 16 February 2019

ER -

Aramis: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).

UN SDGs

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this